Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: Week-192 overall and subgroup analyses from STARTMRK

HIV Clinical Trials

Volumn 13, Issue 4, 2012, Pages 228-232

  Dejesus, Edwin ^a   Rockstroh, Jürgen ^b   Lennox, Jeffrey ^c   Saag, Michael ^d   Lazzarin, Adriano ^e   Zhao, Jing ^f   Wan, Hong ^f   Rodgers, Anthony ^f   Walker, Monica ^f   Miller, Michael ^f   Dinubile, Mark ^f   Nguyen, Bach Yen ^f   Teppler, Hedy ^f   Leavitt, Randi ^f   Sklar, Peter ^f  

^a ORLANDO IMMUNOLOGY CENTER   (United States)

^b UNIVERSITY OF BONN   (Germany)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

efavirenz; raltegravir; STARTMRK; subgroups

Indexed keywords

EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; PLACEBO; RALTEGRAVIR; VIRUS RNA;

ANEMIA; ANTIVIRAL RESISTANCE; ARTICLE; BACKACHE; BASAL CELL CARCINOMA; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG FATALITY; DRUG WITHDRAWAL; ENDOMETRIOSIS; FOOD INTAKE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; KAPOSI SARCOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MENINGITIS; MIGRAINE; MONONUCLEOSIS; PANCREATITIS; PATIENT ATTITUDE; PATIENT SAFETY; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADENINE; ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; DEOXYCYTIDINE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV-1; HUMANS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; PYRROLIDINONES;

EID: 84864693744     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1304-228     Document Type: Article

References (7)

1. Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratana-suwan W, Kovacs C. Sustained antiretroviral efficacy of raltegravir as part of combination antiretroviral therapy in treatment-naive HIV-1 infected patients: 96-week data. J Acquir Immune Defic Syndr. 2008;52:350-356.
2. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359:339-354.
3. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infec-tion. N Engl J Med. 2008;359:355-365.
4. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009;374:796-806.
5. Lennox JL, DeJesus E, Berger DS, et al. Raltegravir ver-sus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr. 2010;55:39-48.
6. Rockstroh JK, Lennox JL, DeJesus E, et al. Long-term treatment with raltegravir or efavirenz combined with teno-fovir/emtricitabine for treatment-naive human immunode-ficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis. 2011;53:807-816.
7. Department of Health and Human Services Panel-Office of AIDS Research Advisory Council. Guidelines for the use of antiretroviral agents in HIV-infected adults and adoles-cents. 2011. http://www.aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL.pdf. Accessed September 19, 2011.